Jeong-Tae Ju
Director/Board Member at KOREA UNITED PHARM INC.
Network origin in Jeong-Tae Ju first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 11 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Jeong-Tae Ju via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| Chung-Ang University | College/University | Doctorate Degree Graduate Degree Graduate Degree Doctorate Degree | |
| Hankuk University of Foreign Studies | College/University | Undergraduate Degree | |
Kyung Hee University
 Kyung Hee University Other Consumer ServicesConsumer Services Kyung Hee University provides academic courses and grants academic degrees. It has udergraduate, graduate, international student, and international faculty programs. The firm also provides scholarships and operates Kyung Hee Medical Center, Kyung Hee University Hospital at Gangdong, and Kangnam Korean Hospital. The company was founded on February 15, 1949 and is headquartered in Seoul, South Korea. | College/University | Doctorate Degree | |
| United Douglas Pharm, Inc | Chief Executive Officer | ||
| Wonkwang University | College/University | Undergraduate Degree | |
| Yonsei University | College/University | Graduate Degree | |
| Kangwon National University | College/University | Doctorate Degree | |
| Daegu University | College/University | Undergraduate Degree | |
| Seoul National University | College/University | Corporate Officer/Principal | |
Pelemed Co., Ltd.
 Pelemed Co., Ltd. Pharmaceuticals: GenericHealth Technology Pelemed Co., Ltd. is a South Korean company based in Seoul that specializes in the development of innovative anticancer drugs. Pelemed's technology platform, PeLeSeLect & AHEDD, overcomes mutation-mediated drug resistance and enables precision drug design for kinase-targeted therapies. The company's pipeline includes several drugs in various stages of development for the treatment of different types of cancer. Pelemed has received funding from the IP Voucher Funded by MSS and has a scientific advisory board that includes experts from the ASAN Medical Center Bio Core Facility. The company was founded in 2019, and its CEOs are Yong-Chul Kim and Soo-Yeon Jang. | Pharmaceuticals: Generic | Director/Board Member |
Statistics
International
| South Korea | 10 |
| United States | 2 |
Sectoral
| Consumer Services | 9 |
| Health Technology | 2 |
Operational
| Director/Board Member | 8 |
| Corporate Officer/Principal | 8 |
| Doctorate Degree | 4 |
| Chief Executive Officer | 3 |
| Undergraduate Degree | 3 |
Most connected contacts
| Insiders | |
|---|---|
| Duk-Young Kang | 4 |
| Gun-Wook Kang | 3 |
| Gui-Ja Kim | 2 |
| Jin-Ho Cho | 2 |
| Yong-Woo Cho | 2 |
| Won-Ho Kang | 2 |
| Hyung-Rae Kim | 2 |
| Won-Tae Jeong | 2 |
| Yeon-Woong Choi | 2 |
| In-Cheol Choi | 2 |
| Won-Il Kal | 1 |
- Stock Market
- Insiders
- Jeong-Tae Ju
- Company connections
